Vimta Labs Limited (IN:VIMTALABS)
:VIMTALABS
Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹25.44B
Enterprise Value₹23.68B
Total Cash (Recent Filing)₹564.64M
Total Debt (Recent Filing)₹67.97M
Price to Earnings (P/E)32.8
Beta1.06
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)17.65
Shares Outstanding44,669,353
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage Balance SheetA near-zero debt position and steadily rising equity materially reduce financial risk, giving management durable capacity to fund laboratory expansion, absorb cyclical downturns, and pursue selective investments or M&A without relying on costly external financing. This supports long-term operational stability and strategic optionality.
Healthy, High MarginsSustained mid-to-high teen net margins and mid-30% EBITDA margins indicate strong pricing power and operational scalability in contract testing and clinical services. Durable margin profile supports reinvestment in specialized labs, funds organic growth and protects profitability through industry cycles and competitive pricing pressure.
Consistent Revenue Growth TrendA multi-year growth trend (c.16% revenue growth) reflects structural demand for outsourced analytical and clinical services as pharma and biotech outsource testing. Durable top-line momentum helps improve capacity utilization, supports scale benefits and strengthens long-term customer relationships and recurring contract revenues.
Bears Say
Margin Volatility And Mix RiskMarked shifts in gross and operating margins suggest exposure to mix changes, competitive pricing or cost variability. This reduces predictability of future profitability, complicates planning for lab capacity and staffing, and could erode long-term return on incremental revenue if higher-margin work proves episodic.
Uneven Free Cash Flow ConversionIntermittent negative FCF and wide year-to-year swings imply working-capital sensitivity and periodic heavy reinvestment. Over a multi-month horizon, this can constrain discretionary spending, delay lab upgrades, raise reliance on internal timing of receivables, and limit consistent funding for dividends or large strategic moves.
Returns Not ExpandingStable but stagnant mid-teens ROE suggests the company has yet to meaningfully improve capital efficiency despite growth. This may reflect limited operating leverage, reinvestment diluting returns, or slower margin expansion, constraining long-term return enhancement and investor upside from improved profitability metrics.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹25.44B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Aug 14, 2026 which is in 51 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on May 06, 2026. The company reported ₹4.726 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.726.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.16%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,669,353 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.726 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.338%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―